About ISTA Pharmaceuticals
ISTA Pharmaceuticals is a Healthcare company based in Irvine (United States) founded in 1992, and was acquired by Bausch & Lomb in March 2012. Eye care pharmaceutical company. ISTA Pharmaceuticals has raised $149 million across 4 funding rounds from investors including Bausch & Lomb, Credit Suisse and Ontario Teachers' Pension Plan. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Annexon and Aldeyra; 3 of its 3 listed competitors have raised funding.
Company details
ISTA Pharmaceuticals offers prescription eye care in the US with an expanding focus on allergy therapeutics. Currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The companys development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. The company generated revenues of 160 million in 2011. Was acquired by Bausch and Lomb in Mar 2012. In July 2013, Bausch and Lomb was acquired by Valeant.
- Headquarters Irvine, United States
- Stage Acquired
- SectorsHealthcare
- Website istavision.com
- Social LinkedIn
- Acquired by Bausch & Lomb (Mar 2012)
- Total Equity Funding$149M (USD)
in 4 rounds
- Latest Funding Round$65M (USD), Private Equity Round
Sep 2008
- InvestorsBausch & Lomb
& 9 more
- Acquired byBausch & Lomb
(Mar 2012)
Funding Insights of ISTA Pharmaceuticals
ISTA Pharmaceuticals has successfully raised a total of $149M across 4 strategic funding rounds. The most recent funding activity was a Private Equity Round of $65 million completed in September 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $149M
- Total Rounds 4
- Last Round Private Equity Round — $65M
- Investors Count 9
All 4 funding rounds of ISTA Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2008 | $65M | Private Equity Round | – | – | |
| Nov 2002 | $40M | Private Equity Round | – | sprout group, Sanderling Ventures | – |
| Sep 2002 | $44M | Private Equity Round | – | – | |
| Jun 2002 | Private Equity Round | – | – |
10 investors in total: 10 institutional.
Investors in ISTA Pharmaceuticals
ISTA Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Bausch & Lomb, Credit Suisse and Ontario Teachers' Pension Plan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical investment financing and active management services. | sanderling.com | |||
Private equity single family office | msdcapital.com | New York, United States | ||
Limited information is provided about KBL Healthcare Ventures. | kblhealthcare.com | |||
Corporate-backed venture capital firm focused on fintech, energy, and multiple sectors | investorgrowthcapital.com | New York, United States | ||
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
Provides asset management and investment advisory services. | 1994 | deerfieldcapital.com | Springfield, United States | |
Wealth management, asset management, and investment banking services are offered. | 1856 | credit-suisse.com | Zurich, Switzerland | |
Provides consulting services for startup execution, digital marketing, and strategic planning. | sproutgroup.co | New York, United States | ||
Pension funds focused on multiple sectors | 1990 | otpp.com | Toronto, Canada | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States |
Investor details for ISTA Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ISTA Pharmaceuticals
4 dated milestones of ISTA Pharmaceuticals across 20 years, from founding to its latest funding, stage changes and deals.
- Founded ISTA Pharmaceuticals is founded.
- Funding First funding round.
- Funding Latest funding round, Private Equity Round, of $65.0M.
- Exit Acquired by Bausch & Lomb.
Competitors of ISTA Pharmaceuticals
ISTA Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Annexon and Aldeyra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. |
Detailed competitors of ISTA Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Ophthalmology
3 companies that operate in the same segment as ISTA Pharmaceuticals (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ISTA Pharmaceuticals
ISTA Pharmaceuticals was founded in 1992 and raised its 1st funding round 10 years after it was founded.
ISTA Pharmaceuticals is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
ISTA Pharmaceuticals is a funded company, having raised a total of $149M across 4 funding rounds to date.
ISTA Pharmaceuticals offers prescription eye care in the US with an expanding focus on allergy therapeutics. Currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The companys development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. The company generated revenues of 160 million in 2011. Was acquired by Bausch and Lomb in Mar 2012. In July 2013, Bausch and Lomb was acquired by Valeant.
ISTA Pharmaceuticals's top competitors include Annexon, Aldeyra and Kriya Therapeutics.
ISTA Pharmaceuticals has 10 investors. Key investors include Bausch & Lomb, Credit Suisse, Ontario Teachers' Pension Plan, Deerfield Triarc Capital, and Sanderling Ventures.
Yes. ISTA Pharmaceuticals was acquired by Bausch & Lomb in March 2012.